Document Detail

Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer.
MedLine Citation:
PMID:  21783358     Owner:  NLM     Status:  Publisher    
Hepatic arterial infusion (HAI) selectively achieves high drug exposure of liver metastases from colorectal cancer. Such pharmacologic advantage has doubled the response rate of liver metastases on fluoropyrimidines (FP) delivered as HAI rather than intravenously, in a meta-analysis of randomised clinical trials (RCT). However, the improvement in antitumour efficacy did not consistently translate into any significant survival advantage across all randomised studies. However, the results of this meta-analysis should be cautiously interpreted due to the heterogeneity of the studies, inadequate study designs, obsolete therapy and high rate of early treatment discontinuation due to HAI technical failures or hepato-biliary toxicity. Most studies actually were performed before year 2000 and did not integrate the considerable progresses accomplished in the management of CRC, such as multidrug regimens instead of single agent FP and secondary resection of metastases, a major contributing factor for prolonged survival. Furthermore, the systemic exposure of patients given HAI was low without concomitant IV therapy, facilitating extra-hepatic relapses. The role of HAI in liver metastases from CRC should, therefore, be revisited, using modern multidisciplinary therapeutic approaches and appropriate study designs. Recommendations for the design of future RCTs exploring HAI are provided.
M Bouchahda; F Lévi; R Adam; P Rougier
Related Documents :
18628068 - Circulating tumor cells in breast cancer: methodology and clinical repercussions.
21913018 - Two decades of experience with hepatic cryotherapy for advanced colorectal metastases.
11803138 - The combined use of radiotherapy and chemotherapy in the treatment of solid tumours.
21769078 - Locoregional therapy for hepatocellular carcinoma: radioembolization with yttrium-90 mi...
15450578 - Surgical treatment of neuroendocrine tumors of the lung.
9271838 - Immunohistochemically detected her-2/neu-expression and prognosis in endometrial carcin...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-7-21
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  -     ISSN:  1879-0852     ISO Abbreviation:  -     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-7-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
INSERM, UMR S776 "Biological Rhythms and cancers", Hospital Paul Brousse, 94800 Villejuif, France; Assistance Publique-Hôpitaux de Paris, Chronotherapy Unit, Department of Medical Oncology and Hepatobiliary Center, Hospital Paul Brousse, 94800 Villejuif, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New opportunities for biocatalysis: driving the synthesis of chiral chemicals.
Next Document:  2-Phenyl and 2-heterocyclic-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridines as inhibitors of TGF-?1 an...